Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

Agents that target components of the PI3K/AKT/mTOR pathway are under investigation for the treatment of diffuse large B cell lymphoma (DLBCL). Given the highly heterogeneous nature of DLBCL, it is not clear whether all subtypes of DLBCL will be susceptible to PI3K pathway inhibition, or which kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezell, Scott A., Wang, Suping, Bihani, Teeru, Lai, Zhongwu, Grosskurth, Shaun E., Tepsuporn, Suprawee, Davies, Barry R., Huszar, Dennis, Byth, Kate F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891033/
https://www.ncbi.nlm.nih.gov/pubmed/26824321
http://dx.doi.org/10.18632/oncotarget.7036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891033/
https://www.ncbi.nlm.nih.gov/pubmed/26824321
http://dx.doi.org/10.18632/oncotarget.7036

Ejemplares similares